COMPARISON OF HISTOLOGICAL COMPOSITIONS AND APOPTOSIS IN CANINE SPONTANEOUS BENIGN PROSTATIC HYPERPLASIA TREATED WITH ANDROGEN SUPPRESSIVE AGENTS CHLORMADINONE ACETATE AND FINASTERIDE
- 1 January 2001
- journal article
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 165 (1) , 289-293
- https://doi.org/10.1097/00005392-200101000-00081
Abstract
Purpose: Chlormadinone acetate and finasteride are androgen suppressive agents clinically used for benign prostatic hyperplasia but their mechanism for inducing prostatic atrophy differs. We investigated the effect of these androgen suppressive agents on prostatic histology and apoptosis using the spontaneous canine benign prostatic hyperplasia model. Materials and Methods: Animals were treated with oral chlormadinone acetate or finasteride for 25 weeks. The prostatic volumes were analyzed every 5 weeks. Prostatic androgen and estrogen concentrations, histological composition and apoptosis were determined at the end of treatment. Apoptosis was measured by in situ labeling of 3′ hydroxy ends of the DNA breaks using the terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end-labeling method. Results: There was a similar volume reduction effect with 0.3 mg./kg. chlormadinone acetate daily and 1 mg./kg. finasteride daily. Chlormadinone acetate decreased testosterone and dihydrotestosterone but finasteride decreased only dihydrotestosterone in the prostate gland. The concentration ratio of estradiol-to-total androgen in the prostate was significantly increased in finasteride treated canines. Chlormadinone acetate and finasteride decreased the epithelial and stromal components. The extent of apoptosis observed in the prostate was significantly higher in the chlormadinone acetate group compared to that of the control and finasteride groups. Conclusions: Although a similar effect of chlormadinone acetate and finasteride was observed in the induction of prostatic regression and composition of the histological components, the sustained increase in apoptosis was observed only in chlormadinone acetate treated canines. We suggest that different intraprostatic endocrine environments created by chlormadinone acetate or finasteride, which have different intraprostatic testosterone levels and estradiol-to-androgen ratios, may be responsible for the different outcomes in the extent of apoptosis.Keywords
This publication has 20 references indexed in Scilit:
- Long-term effects of finasteride on prostate tissue compositionUrology, 1999
- Estimation of canine prostatic volume: nomogram based on prostatic cubic volume.International Urology and Nephrology, 1998
- Maximum Efficacy of Finasteride Is Obtained within 6 Months and Maintained over 6 YearsEuropean Urology, 1998
- Efficacy and tolerability of finasteride in symptomatic benign prostatic hyperplasia: a primary care studyClinical Therapeutics, 1997
- Expression and Degradation of Rat Androgen Receptor Following Castration, Testosterone Replacement and Antiandrogens Administration: Analysis by Western Blot and Immunohistochemistry.The Tohoku Journal of Experimental Medicine, 1997
- Efficacy, tolerability, and effect on health-related quality of life of finasteride versus placebo in men with symptomatic benign prostatic hyperplasia: a community-based studyClinical Therapeutics, 1995
- Quantitative evaluation of glandular and stromal compartments in hyperplastic dog prostates: Effect of 5‐alpha reductase inhibitorsThe Prostate, 1995
- Histological evaluation of benign prostatic hyperplasia treated by long-term administration of chlormadinone acetate (CMA)The Prostate, 1994
- Effects of Oral Administration of Chlormadinone Acetate on Canine Prostatic HypertrophyThe Journal of Veterinary Medical Science, 1993
- THF EARLY STAGES OF ABSORPTION OF INJECTED HORSERADISH PEROXIDASE IN THE PROXIMAL TUBULES OF MOUSE KIDNEY: ULTRASTRUCTURAL CYTOCHEMISTRY BY A NEW TECHNIQUEJournal of Histochemistry & Cytochemistry, 1966